Abstract:Abstract Background Abnormal DNA methylation is observed as an early event in breast carcinogenesis. However, how such alterations arise is still poorly understood. microRNAs (miRNAs) regulate gene expression at the post-transcriptional level and play key roles in various biological processes. Here, we integrate miRNA expression and DNA methylation at CpGs to study how miRNAs may affect the breast cancer methylome and how DNA methylation may regulate miRNA expression. Methods miRNA expression and DNA methylation data from two breast cancer cohorts, Oslo2 ( n = 297) and The Cancer Genome Atlas ( n = 439), were integrated through a correlation approach that we term miRNA-methylation Quantitative Trait Loci (mimQTL) analysis. Hierarchical clustering was used to identify clusters of miRNAs and CpGs that were further characterized through analysis of mRNA/protein expression, clinicopathological features, in silico deconvolution, chromatin state and accessibility, transcription factor binding, and long-range interaction data. Results Clustering of the significant mimQTLs identified distinct groups of miRNAs and CpGs that reflect important biological processes associated with breast cancer pathogenesis. Notably, two major miRNA clusters were related to immune or fibroblast infiltration, hence identifying miRNAs associated with cells of the tumor microenvironment, while another large cluster was related to estrogen receptor (ER) signaling. Studying the chromatin landscape surrounding CpGs associated with the estrogen signaling cluster, we found that miRNAs from this cluster are likely to be regulated through DNA methylation of enhancers bound by FOXA1, GATA2, and ER-alpha. Further, at the hub of the estrogen cluster, we identified hsa-miR-29c-5p as negatively correlated with the mRNA and protein expression of DNA methyltransferase DNMT3A, a key enzyme regulating DNA methylation. We found deregulation of hsa-miR-29c-5p already present in pre-invasive breast lesions and postulate that hsa-miR-29c-5p may trigger early event abnormal DNA methylation in ER-positive breast cancer. Conclusions We describe how miRNA expression and DNA methylation interact and associate with distinct breast cancer phenotypes.

Crosstalk between Methylation and ncRNAs in Breast Cancer: Therapeutic and Diagnostic Implications

Non-coding RNA Methylation Modifications in Hepatocellular Carcinoma: Interactions and Potential Implications

RNA methylation and breast cancer: insights into m6A, m7G and m5C

Unraveling the cross‐talk between N6‐methyladenosine modification and non‐coding RNAs in breast cancer: Mechanisms and clinical implications

Crosstalk between miRNAs and DNA Methylation in Cancer

The Mechanism of DNA Methylation and miRNA in Breast Cancer

The Landscape of DNA Methylation-Mediated Regulation of Long Non-Coding RNAs in Breast Cancer

Metabolism-regulating non-coding RNAs in breast cancer: roles, mechanisms and clinical applications

Methylation modification of non-histone proteins in breast cancer: an emerging targeted therapeutic strategy

Critical Roles and Clinical Perspectives of RNA Methylation in Cancer

Multidimensional Communication of Micrornas and Long Non-Coding RNAs in Lung Cancer

Insights into the Role of Long Non-Coding RNAs in DNA Methylation Mediated Transcriptional Regulation

Epigenetic modulations of noncoding RNA: a novel dimension of Cancer biology

Methylomics and cancer: the current state of methylation profiling and marker development for clinical care

Potential therapies for non-coding RNAs in breast cancer

Crosstalk Between m6A RNA Methylation and miRNA Biogenesis in Cancer: An Unholy Nexus

Effects of Differentially Methylated CpG Sites in Enhancer and Promoter Regions on the Chromatin Structures of Target LncRNAs in Breast Cancer

New understandings of the genetic regulatory relationship between non-coding RNAs and m6A modification

Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancer

Dynamic M6a-Ncrnas Association and Their Impact on Cancer Pathogenesis, Immune Regulation and Therapeutic Response